Biggest AI Rivals Agree They Need to Slow It Down

Elon Musk and Sam Altman supported Anthropic boss Dario Amodei's call for curbs on breakneck development. Altman even suggested OpenAI may delay its IPO to focus on safety.

AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial

The Etcamah results came a week after the U.S. granted approval for the drug for advanced breast cancer upon the detection of a specific mutation.

Forget Robot Workers, This Company Wants to Build Soldiers